These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6404709)

  • 41. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major.
    Suvarna J; Ingle H; Deshmukh CT
    Indian Pediatr; 2006 May; 43(5):393-400. PubMed ID: 16735760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defective vitamin D metabolism in thalassemia major.
    Zaino EC; Yeh JK; Aloia J
    Ann N Y Acad Sci; 1985; 445():127-34. PubMed ID: 3874574
    [No Abstract]   [Full Text] [Related]  

  • 43. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA; Flynn DM; Barry M
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract]   [Full Text] [Related]  

  • 44. The development of new drugs for use in iron chelation therapy.
    Grady RW
    Birth Defects Orig Artic Ser; 1976; 12(8):161-75. PubMed ID: 795480
    [No Abstract]   [Full Text] [Related]  

  • 45. High-dose chelation therapy in thalassaemia.
    Lancet; 1984 Feb; 1(8373):373-4. PubMed ID: 6141429
    [No Abstract]   [Full Text] [Related]  

  • 46. Iron chelation in thalassemia.
    Pippard MJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):35-40. PubMed ID: 3390560
    [No Abstract]   [Full Text] [Related]  

  • 47. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

  • 48. [Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major].
    Zeĭnalova AA; Ragimov AA; Dashkova NG; Mamedova FR; Kurbanova SA
    Pediatriia; 1987; (2):55-60. PubMed ID: 3575062
    [No Abstract]   [Full Text] [Related]  

  • 49. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA; Oski FA
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract]   [Full Text] [Related]  

  • 50. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 51. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major.
    Najafipour F; Aliasgarzadeh A; Aghamohamadzadeh N; Bahrami A; Mobasri M; Niafar M; Khoshbaten M
    Ann Saudi Med; 2008; 28(5):361-6. PubMed ID: 18779644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
    Barry M; Flynn DM; Letsky EA; Risdon RA
    Br Med J; 1974 Apr; 2(5909):16-20. PubMed ID: 4821036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New treatment for patients with iron overload.
    Griffith P; Burks J
    J Nurs Care; 1978 Sep; 11(9):12-4. PubMed ID: 308223
    [No Abstract]   [Full Text] [Related]  

  • 54. Chelation therapy for the treatment of thalassemia.
    Graziano JH; Cerami A
    Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766
    [No Abstract]   [Full Text] [Related]  

  • 55. Chelation therapy and cardiac status in young patients with thalassemia major.
    Roodpeyma S; Alebouye M; Kamali Z
    J Trop Pediatr; 2000 Jun; 46(3):179. PubMed ID: 10893922
    [No Abstract]   [Full Text] [Related]  

  • 56. Thalassemia in Britain and Australia.
    Modell B; Matthews R
    Birth Defects Orig Artic Ser; 1976; 12(8):13-29. PubMed ID: 795477
    [No Abstract]   [Full Text] [Related]  

  • 57. [Detection of diabetes mellitus in the district of Trencín].
    Kratinová R; Hudáková G
    Vnitr Lek; 1971 Jul; 17(7):665-72. PubMed ID: 5564645
    [No Abstract]   [Full Text] [Related]  

  • 58. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract]   [Full Text] [Related]  

  • 59. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.